Table 2.
Baseline characteristics of patients according to re-TUR status and the presence or absence of muscle in the specimen of the first TUR
| Variable | No muscle, no reTUR (%) | No muscle, reTUR (%) | Muscle, no reTUR (%) | Muscle, reTUR (%) | Unknown (%) | All Patients (%) |
|---|---|---|---|---|---|---|
|
| ||||||
| N | 130 | 276 | 1092 | 624 | 329 | 2451 |
|
| ||||||
| Age | ||||||
| < 70 yrs | 74 (5.3) | 173 (12.5) | 582 (42.0) | 361 (26.1) | 195 (14.1) | 1385 (56.5) |
| ≥ 70 yrs | 56 (5.3) | 103 (9.7) | 510 (47.8) | 263 (24.7) | 134 (12.6) | 1066 (43.5) |
| Median (yrs) | 68 | 65 | 69 | 68 | 67 | 68 |
| Interquartile range (yrs) | 61–75 | 57–73 | 61–75 | 60–74 | 61–74 | 60–74 |
|
| ||||||
| Sex | ||||||
| Male | 101 (5.0) | 217 (10.8) | 907 (45.1) | 512 (25.5) | 275 (13.7) | 2012 (82.1) |
| Female | 29 (6.6) | 59 (13.4) | 185 (42.1) | 112 (25.5) | 54 (12.3) | 439 (17.9) |
|
| ||||||
| Tumor status | ||||||
| Primary T1G3 | 110 (5.1) | 244 (11.2) | 967 (44.4) | 575 (26.4) | 283 (13.0) | 2179 (88.9) |
| Recurrent after non T1G3 | 20 (7.4) | 32 (11.8) | 125 (46.0) | 49 (18.0) | 46 (16.9) | 272 (11.1) |
|
| ||||||
| Previous intravesical chemotherapy | ||||||
| No | 118 (5.1) | 263 (11.3) | 1031 (44.4) | 598 (25.8) | 310 (13.4) | 2320 (94.7) |
| Yes | 12 (9.2) | 13 (9.9) | 61 (46.6) | 26 (19.9) | 19 (14.5) | 131 (5.3) |
|
| ||||||
| Tumor focality | ||||||
| Solitary | 47 (4.9) | 35 (3.6) | 539 (55.9) | 178 (18.5) | 165 (17.1) | 964 (39.3) |
| Multiple | 48 (3.5) | 238 (17.4) | 541 (39.6) | 438 (32.1) | 100 (7.3) | 1365 (55.7) |
| Missing/Unknown | 35 (28.7) | 3 (2.5) | 12 (9.8) | 8 (6.6) | 64 (52.5) | 122 (5.0) |
|
| ||||||
| Largest tumor diameter | ||||||
| < 3 cm | 65 (5.7) | 35 (3.1) | 684 (60.2) | 210 (18.5) | 143 (12.6) | 1137 (46.4) |
| ≥ 3 cm | 24 (4.3) | 29 (5.2) | 291 (52.0) | 152 (27.1) | 64 (11.4) | 560 (22.8) |
| Missing/Unknown | 41 (5.4) | 212 (28.1) | 117 (15.5) | 262 (34.8) | 122 (16.2) | 754 (30.8) |
|
| ||||||
| Concomitant CIS | ||||||
| No | 103 (5.6) | 215 (11.6) | 814 (44.0) | 454 (24.5) | 266 (14.4) | 1852 (75.6) |
| Yes | 27 (4.5) | 61 (10.2) | 278 (46.4) | 170 (28.4) | 63 (10.5) | 599 (24.4) |
|
| ||||||
| Invasion of prostatic urethra | ||||||
| No | 82 (6.1) | 53 (4.0) | 812 (60.7) | 342 (25.6) | 48 (3.6) | 1337 (54.6) |
| Yes, without stromal invasion | 0 | 2 (4.6) | 25 (56.8) | 16 (36.4) | 1 (2.3) | 44 (1.8) |
| Yes, with stromal invasion | 0 | 1 (20.0) | 2 (40.0) | 2 (40.0) | 0 | 5 (0.2) |
| Missing/Unknown | 48 (4.5) | 220 (20.7) | 253 (23.8) | 264 (24.8) | 280 (26.3) | 1065 (43.4) |
|
| ||||||
| Pathology at restaging TUR* | ||||||
| No residual tumor | NA | 39 (14.1) | NA | 217 (34.8) | 11 (3.3) | 267 (28.6) |
| Ta | NA | 126 (45.7) | NA | 240 (38.5) | 12 (3.6) | 378 (40.4) |
| T1 | NA | 111 (40.2) | NA | 166 (26.6) | 12 (3.6) | 289 (30.9) |
| CIS | NA | NA** | NA | NA** | NA** | NA** |
| Missing/Unknown | NA | 0 | NA | 1 (.02) | NA | 1 (0.1) |
|
| ||||||
| Maintenance BCG | ||||||
| No | 89 (5.9) | 245 (16.2) | 627 (41.4) | 373 (24.6) | 181 (12.0) | 1515 (61.8) |
| Yes | 41 (4.4) | 31 (3.3) | 465 (49.7) | 251 (26.8) | 148 (15.8) | 936 (38.2) |
**
Separate information on CIS at re-TUR was not available.